TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients
Brief Summary: This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.


Options:
A: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Spironolactone + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone, Drug: Placebo | Arm Label: Double Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone + L-arginine; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone, Dietary Supplement: L-arginine | Arm Label: L-arginine + Placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: L-arginine, Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone + L-arginine, Spironolactone + Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: L-arginine; Assigned to Arm(s): L-arginine + Placebo, Spironolactone + L-arginine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double Placebo, L-arginine + Placebo, Spironolactone + Placebo
C: Arm Label: Eplerenone group; Type: EXPERIMENTAL; Interventions: Drug: Eplerenone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: spironolactone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Comparison of Virtual Colonoscopy, Optical Colonoscopy, and Fecal Occult Blood Testing for Colorectal Cancer Screening: a Pilot Study
Brief Summary: Colon cancer is the second leading cause of cancer death in North America. These deaths are preventable with proper screening. Fecal occult blood testing, virtual colonoscopy, and standard (optical) colonoscopy are all options for colon cancer screening, but it is not known which is the best at preventing death from colon cancer. A large study comparing these three tests is desperately needed. In this pilot study, the investigators want to find out what percentage of patients will show up for their screening test once enrolled. This will provide crucial information for the successful execution of the larger study.


Options:
A: Arm Label: Fecal Occult Blood Test; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal occult blood test | Arm Label: Virtual Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Virtual colonoscopy | Arm Label: Optical Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Optical colonoscopy | Intervention Type: OTHER; Name: Fecal occult blood test; Assigned to Arm(s): Fecal Occult Blood Test | Intervention Type: PROCEDURE; Name: Virtual colonoscopy; Assigned to Arm(s): Virtual Colonoscopy | Intervention Type: PROCEDURE; Name: Optical colonoscopy; Assigned to Arm(s): Optical Colonoscopy
B: Arm Label: telephone; Type: EXPERIMENTAL; Interventions: Behavioral: telephone | Arm Label: face-to-face; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: consultation face-to-face | Intervention Type: BEHAVIORAL; Name: telephone; Assigned to Arm(s): telephone | Intervention Type: BEHAVIORAL; Name: consultation face-to-face; Assigned to Arm(s): face-to-face
C: Intervention Type: DRUG; Name: VRC-FLUDNA047-00-VP; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Flulaval (Registered) Seasonal Influenza Vaccine; Assigned to Arm(s): N/A
D: Arm Label: Culturally-tailored video; Type: OTHER; Interventions: Behavioral: Culturally-tailored video | Intervention Type: BEHAVIORAL; Name: Culturally-tailored video; Assigned to Arm(s): Culturally-tailored video

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DHA, Inflammation, and Insulin Sensitivity
Brief Summary: Women with excess adiposity while pregnant are more likely to develop gestational diabetes and high blood pressure during pregnancy than women of healthy weights. This may occur because overweight and obese pregnant women are less sensitive to insulin and have more inflammation than pregnant women of healthy weights. This study will examine the effect of a nutritional supplement, docosahexaenoic acid (DHA), on improving insulin sensitivity and lessening inflammation in overweight and obese pregnant women.


Options:
A: Arm Label: DHA supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA Supplementation | Arm Label: Control (milk without DHA); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control (milk without DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplementation; Assigned to Arm(s): DHA supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (milk without DHA); Assigned to Arm(s): Control (milk without DHA)
B: Arm Label: Docosa-hexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Docosa-hexaenoic acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosa-hexaenoic acid (DHA); Assigned to Arm(s): Docosa-hexaenoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA Supplements | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplements; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Supplements; Assigned to Arm(s): 2
D: Arm Label: Fish-Oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fish oil, Ocean plus | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil, Ocean plus; Assigned to Arm(s): Fish-Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study to Test Feasibility, Safety, Molecular Mediators and Preliminary Efficacy of Remote Myocardial Postconditioning Provided With Extrinsic Cuff Compression of Lower Limb During Primary PCI
Brief Summary: Background: Experimental studies suggest that remote limb ischaemic postconditioning (RemPostCon) can reduce infarct size in pigs. Initial clinical applications support the beneficial role of RemPostCon in preserving endothelial function during upper limb ischemia in healthy volunteers and in patients with stable coronary artery disease.

Aim of the study: To evaluate the feasibility, safety and efficacy of RemPostCon in the setting of STEMI and primary PCI (pPCI) and to investigate potential circulating mediators of its effects.

Patients and methods: Patients who undergo pPCI for anterior STEMI within 6 hours since the onset of symptoms are randomly assigned to receive either RemPostCon + pPCI or pPCI alone in a single-blind fashion. All patients receive therapy according to the current international guidelines. Three cycles of ischemia-reperfusion are provided to the lower limb inflating a cuff to 200 mmHg. Each cycle consists of 5' of ischaemia, followed by 5' of reperfusion. RemPostCon is started at the time of angioplasty in the infarct related artery. Primary endpoint is the area under the curve (AUC) of creatinine kinase - MB (CK - MB). Cardiac magnetic resonance (CMR) is performed early before discharge and 4 months after the event, if there are no contraindications.


Options:
A: Arm Label: Sevoflurane; Type: EXPERIMENTAL; Interventions: Procedure: Sevoflurane preconditioning | Arm Label: No Sevoflurane; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Sevoflurane preconditioning; Assigned to Arm(s): Sevoflurane
B: Arm Label: RemotePostConditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote Postconditioning | Arm Label: Controls; Type: SHAM_COMPARATOR; Interventions: Procedure: Remote Postconditioning | Intervention Type: PROCEDURE; Name: Remote Postconditioning; Assigned to Arm(s): Controls, RemotePostConditioning
C: Arm Label: Thrombolysis + Remote perconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Thrombolysis + remote perconditioning | Arm Label: Thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Actilyse | Intervention Type: DRUG; Name: Actilyse; Assigned to Arm(s): Thrombolysis | Intervention Type: PROCEDURE; Name: Thrombolysis + remote perconditioning; Assigned to Arm(s): Thrombolysis + Remote perconditioning
D: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation
Brief Summary: The primary objective of the study was to evaluate the safety and tolerability of VX-809 in participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: N91115 + Rifampin; Type: EXPERIMENTAL; Interventions: Drug: N91115, Drug: Rifampin | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): N91115 + Rifampin | Intervention Type: DRUG; Name: Rifampin; Assigned to Arm(s): N91115 + Rifampin
C: Arm Label: TEZ/IVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TEZ/IVA, Drug: IVA, Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA, Drug: Placebo | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA, VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): VX-445/TEZ/IVA TC
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study of VX-809 to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of VX-809 in Cystic Fibrosis Subjects Homozygous for the ∆F508-CFTR Gene Mutation
Brief Summary: The primary objective of the study was to evaluate the safety and tolerability of VX-809 in participants with cystic fibrosis (CF) who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene.


Options:
A: Arm Label: Part A: 3 to <24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Arm Label: Part B + A/B:1 to < 24 months; Type: EXPERIMENTAL; Interventions: Drug: IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: 3 to <24 months, Part B + A/B:1 to < 24 months
B: Arm Label: Riociguat (Adempas, BAY63-2521); Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Arm Label: Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Ataluren | Intervention Type: DRUG; Name: Ataluren; Assigned to Arm(s): Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg, Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Exercise Trial for Wheelchair Users
Brief Summary: People with mobility disabilities are at greater risk than the general population for incurring health problems. Many of these conditions are preventable through behavior and lifestyle changes such as exercise and physical activity. Recent evidence suggests that people with disabilities experience the same physiologic response to exercise as the general population. Nonetheless, nearly three-fourths of those with disabilities report being entirely sedentary or not active enough to achieve health benefits. Despite some knowledge of issues that limit physical activity among this population, few studies have investigated methods for promoting physical activity adoption among people with disabilities, including wheelchair users. The purpose of this study is to test the effectiveness of a behavioral intervention to promote physical activity adoption over 6 months and maintenance of physical activity over another 6 months by community-dwelling manual wheelchair users.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Educational session to promote physical activity | Arm Label: 2; Type: OTHER; Interventions: Other: Minimal contact | Intervention Type: OTHER; Name: Educational session to promote physical activity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Minimal contact; Assigned to Arm(s): 2
B: Arm Label: Specific rehabilitation program; Type: EXPERIMENTAL; Interventions: Behavioral: Specific rehabilitation program | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Specific rehabilitation program, Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Specific rehabilitation program; Assigned to Arm(s): Specific rehabilitation program, Usual Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Energetic; Type: EXPERIMENTAL; Interventions: Behavioral: Energetic | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Energetic; Assigned to Arm(s): Energetic | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Standard Care Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care Counseling | Arm Label: Supervised Exercise and Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Exercise and Counseling | Intervention Type: BEHAVIORAL; Name: Standard Care Counseling; Assigned to Arm(s): Standard Care Counseling | Intervention Type: BEHAVIORAL; Name: Supervised Exercise and Counseling; Assigned to Arm(s): Supervised Exercise and Counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. Falciparum Infection in Infants and Children in Africa
Brief Summary: The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Ninos Sanos Familia Sana | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ninos Sanos Familia Sana | Intervention Type: BEHAVIORAL; Name: Ninos Sanos Familia Sana; Assigned to Arm(s): Comparison, Intervention
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: Outreach Facilitation implementing elements of the Chronic Care Model | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Outreach Facilitation implementing elements of the Chronic Care Model; Assigned to Arm(s): intervention
C: Arm Label: Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Family-Skills Training | Intervention Type: BEHAVIORAL; Name: Family-Skills Training; Assigned to Arm(s): Control Group, Intervention Group
D: Arm Label: GSK257049 [5-17M] Group; Type: EXPERIMENTAL; Interventions: Biological: Malaria Vaccine 257049, Biological: Meningococcal C Conjugate Vaccine | Arm Label: GSK257049 [6-12W] Group; Type: EXPERIMENTAL; Interventions: Biological: Malaria Vaccine 257049, Biological: Meningococcal C Conjugate Vaccine, Biological: TritanrixHepB/Hib, Biological: Polio Sabin Oral Polio Vaccine (GSK) | Arm Label: VeroRab Comparator [5-17M] Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Meningococcal C Conjugate Vaccine, Biological: Cell-culture rabies vaccine | Arm Label: Menjugate Comparator [6-12W] Group; Type: EXPERIMENTAL; Interventions: Biological: Meningococcal C Conjugate Vaccine, Biological: TritanrixHepB/Hib, Biological: Polio Sabin Oral Polio Vaccine (GSK) | Intervention Type: BIOLOGICAL; Name: Malaria Vaccine 257049; Assigned to Arm(s): GSK257049 [5-17M] Group, GSK257049 [6-12W] Group | Intervention Type: BIOLOGICAL; Name: Meningococcal C Conjugate Vaccine; Assigned to Arm(s): GSK257049 [5-17M] Group, GSK257049 [6-12W] Group, Menjugate Comparator [6-12W] Group, VeroRab Comparator [5-17M] Group | Intervention Type: BIOLOGICAL; Name: Cell-culture rabies vaccine; Assigned to Arm(s): VeroRab Comparator [5-17M] Group | Intervention Type: BIOLOGICAL; Name: TritanrixHepB/Hib; Assigned to Arm(s): GSK257049 [6-12W] Group, Menjugate Comparator [6-12W] Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin Oral Polio Vaccine (GSK); Assigned to Arm(s): GSK257049 [6-12W] Group, Menjugate Comparator [6-12W] Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brief Summary: This was a study to determine whether therapy with pazopanib was effective and safe in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer had not progressed on first line chemotherapy.


Options:
A: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD
B: Arm Label: A - Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B - Paclitaxel + Bevacizumab followed by Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A - Paclitaxel, B - Paclitaxel + Bevacizumab followed by Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): B - Paclitaxel + Bevacizumab followed by Bevacizumab
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: SPARC-08-038; Type: EXPERIMENTAL; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Arm Label: Ref-08-038; Type: ACTIVE_COMPARATOR; Interventions: Drug: SPARC-08-038, Drug: Ref-08-038 | Intervention Type: DRUG; Name: SPARC-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038 | Intervention Type: DRUG; Name: Ref-08-038; Assigned to Arm(s): Ref-08-038, SPARC-08-038

Answer: C